Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Egger, Matthias
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer	Completed	2	124	Europe	Aflibercept + mLV5FU2, mFOLFOX7	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi	Colorectal Cancer	02/24	02/24
DTG-Resist, NCT06285110: HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen	Recruiting	N/A	2600	RoW		University of Bern, University of Zurich, ETH Zurich, University of KwaZulu, University of Bristol	Hiv	08/25	08/25
DTG-SWITCH, NCT04612452: The Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART	Completed	N/A	2820	RoW		University of Bern, University of KwaZulu, Lighthouse Trust, Centre for Infectious Disease Research in Zambia	Hiv, Drug Resistancy, Virologic Failure	03/23	03/23
OGIPRO, NCT05234021: HER2-directed Biosimilar in Breast Cancer: Real World ePRO	Completed	N/A	52	Europe		OnkoZentrum Zürich AG, University of Zurich, Palleos Healthcare GmbH	HER2-positive Breast Cancer, Biosimilar, Patient Reported Outcome	06/23	06/23
ERYT, NCT04024267: Eurythmy Therapy () as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients	Active, not recruiting	N/A	196	Europe	Eurythmy therapy, CoordiFit	University of Bern, Breast Cancer Research Foundation	Fatigue, Breast Cancer	07/25	07/25